Results 1 - 20 of 13,209 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (12,674)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsCell Reports, 2022-05, Vol.39 (7), p.110812-110812, Article 110812 [Peer Reviewed Journal]2022 The Authors ;Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2022 The Authors 2022 ;ISSN: 2211-1247 ;EISSN: 2211-1247 ;DOI: 10.1016/j.celrep.2022.110812 ;PMID: 35568025Digital Resources/Online E-Resources |
| 2 |
Material Type: Article
|
|
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodiesNature medicine, 2022-03, Vol.28 (3), p.490-495 [Peer Reviewed Journal]2022. The Author(s), under exclusive licence to Springer Nature America, Inc. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01678-y ;PMID: 35046573Full text available |
| 3 |
Material Type: Article
|
|
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial CancerJournal of clinical oncology, 2019-10, Vol.37 (30), p.2786-2794 [Peer Reviewed Journal]2019 by American Society of Clinical Oncology 2019 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.19.01021 ;PMID: 31461377Full text available |
| 4 |
Material Type: Article
|
|
Immune Checkpoint Blockade in Cancer TherapyJournal of clinical oncology, 2015-06, Vol.33 (17), p.1974-1982 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;2015 by American Society of Clinical Oncology 2015 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2014.59.4358 ;PMID: 25605845Full text available |
| 5 |
Material Type: Article
|
|
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studiesNature reviews. Microbiology, 2023-02, Vol.21 (2), p.112-124 [Peer Reviewed Journal]2022. Springer Nature Limited. ;Springer Nature Limited 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;Springer Nature Limited 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1740-1526 ;EISSN: 1740-1534 ;DOI: 10.1038/s41579-022-00809-7 ;PMID: 36307535Full text available |
| 6 |
Material Type: Article
|
|
Targeting HER2-positive breast cancer: advances and future directionsNature reviews. Drug discovery, 2023-02, Vol.22 (2), p.101-126 [Peer Reviewed Journal]2022. Springer Nature Limited. ;Springer Nature Limited 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;Springer Nature Limited 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-022-00579-0 ;PMID: 36344672Full text available |
| 7 |
Material Type: Article
|
|
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron VariantNew England Journal of Medicine, 2022-03, Vol.386 (10), p.995-998 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2119407 ;PMID: 35081300Digital Resources/Online E-Resources |
| 8 |
Material Type: Article
|
|
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer cell, 2015-04, Vol.27 (4), p.450-461 [Peer Reviewed Journal]2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;2015 Published by Elsevier Inc. 2015 ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2015.03.001 ;PMID: 25858804Full text available |
| 9 |
Material Type: Article
|
|
ATP in the tumour microenvironment drives expression of nfP2X 7 , a key mediator of cancer cell survivalOncogene, 2019-01, Vol.38 (2), p.194 [Peer Reviewed Journal]EISSN: 1476-5594 ;DOI: 10.1038/s41388-018-0426-6 ;PMID: 30087439Full text available |
| 10 |
Material Type: Article
|
|
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceThe oncologist (Dayton, Ohio), 2020-01, Vol.25 (1), p.e147-e159 [Peer Reviewed Journal]AlphaMed Press 2019 ;AlphaMed Press 2019. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2019-0244 ;PMID: 31578273Full text available |
| 11 |
Material Type: Article
|
|
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerNature (London), 2017-07, Vol.547 (7662), p.222-226 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Jul 13, 2017 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature23003 ;PMID: 28678784Full text available |
| 12 |
Material Type: Article
|
|
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generationsNature reviews. Drug discovery, 2016-04, Vol.15 (4), p.235-247 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2016 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2015.35 ;PMID: 26965203Full text available |
| 13 |
Material Type: Article
|
|
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of oncology, 2015-12, Vol.26 (12), p.2375-2391 [Peer Reviewed Journal]2015 European Society for Medical Oncology ;The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2015 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdv383 ;PMID: 26371282Full text available |
| 14 |
Material Type: Article
|
|
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinCell, 2021-04, Vol.184 (9), p.2316-2331.e15 [Peer Reviewed Journal]2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.03.029 ;PMID: 33773105Full text available |
| 15 |
Material Type: Article
|
|
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1Cancer cell, 2018-02, Vol.33 (2), p.187-201.e10 [Peer Reviewed Journal]2018 ;Published by Elsevier Inc. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2018.01.009 ;PMID: 29438695Full text available |
| 16 |
Material Type: Article
|
|
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic DiseaseCancer discovery, 2016-12, Vol.6 (12), p.1382-13992016 American Association for Cancer Research. ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.cd-16-0577 ;PMID: 27663893Full text available |
| 17 |
Material Type: Article
|
|
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?British journal of cancer, 2017-12, Vol.117 (12), p.1736-1742 [Peer Reviewed Journal]Copyright Nature Publishing Group Dec 5, 2017 ;Copyright © 2017 The Author(s) 2017 The Author(s) ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2017.367 ;PMID: 29065110Full text available |
| 18 |
Material Type: Article
|
|
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapyGut, 2022-04, Vol.71 (4), p.734-745 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2022 ;ISSN: 0017-5749 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2020-321031 ;PMID: 34006584Full text available |
| 19 |
Material Type: Article
|
|
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapyNature communications, 2016-01, Vol.7 (1), p.10582-10582, Article 10582 [Peer Reviewed Journal]Copyright Nature Publishing Group Jan 2016 ;Copyright © 2016, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms10582 ;PMID: 26822383Full text available |
| 20 |
Material Type: Article
|
|
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaThe New England journal of medicine, 2018-06, Vol.378 (26), p.2486-2496 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1804092 ;PMID: 29782217Full text available |
Results 1 - 20 of 13,209 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (12,674)
Refine My Results
Creation Date
- Before 1990 (129)
- 1990 To 1997 (2,409)
- 1998 To 2005 (4,072)
- 2006 To 2014 (4,157)
- After 2014 (2,442)
-
More options
New Records
Resource Type
- Articles (13,204)
- magazinearticle (3)
- Web Resources (2)
-
More options
Subject
- Antibodies, Monoclonal - Pharmacology (13,203)
- Science & Technology (11,433)
- Life Sciences & Biomedicine (10,816)
- Humans (9,265)
- Animals (7,882)
- Mice (5,303)
- Biological And Medical Sciences (4,042)
- Female (3,650)
- Immunology (3,405)
- Male (2,938)
- Medical Sciences (2,920)
- Oncology (2,670)
- Antibodies, Monoclonal - Immunology (2,304)
- Antibodies, Monoclonal - Therapeutic Use (2,139)
- Cell Line, Tumor (1,744)
- Cells, Cultured (1,602)
- Cell Biology (1,552)
- Monoclonal Antibodies (1,472)
- Mice, Inbred Balb C (1,433)
- Antineoplastic Agents - Pharmacology (1,380)
-
More options
Databases
- MEDLINE (13,203)
- GFMER Free Medical Journals (7,468)
- HighWire Press (Free Journals) (4,745)
- ProQuest Central (4,066)
- PubMed Central (4,012)
- DOAJ Directory of Open Access Journals (2,226)
- ROAD: Directory of Open Access Scholarly Resources (1,365)
- Wiley Online Library Open Access (1,291)
- IngentaConnect Open Access Journals (652)
- Nature Free (578)
- Springer Nature OA Free Journals (531)
- Public Library of Science (PLoS) (278)
- JSTOR Early Journal Content (239)
- Taylor & Francis Open Access (216)
- Free E- Journals (202)
- ProQuest One Psychology (190)
- Cell Press Free Archives (137)
- Freely Accessible Japanese Titles (127)
- Hyper Article en Ligne (HAL) (Open Access) (104)
- Mary Ann Liebert Online - Open Access (103)
-
More options
Language
Journal Title
- Blood (610)
- Cancer Research (418)
- Clinical Cancer Research (307)
- International Immunology (146)
- Journal Of Leukocyte Biology (180)
- Molecular Cancer Therapeutics (197)
- Plos One (248)
- Proceedings Of The National Academy Of Sciences - Pnas (176)
- The Journal Of Biological Chemistry (246)
- The Journal Of Immunology (931)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||